The small shortfalls that tip the race

Paper 8d · Treat at the base, not the top · Read on Zenodo

Nobody is born with ADHD. You are born with a biological starting point: some genes, some enzymes, a need for particular vitamins and minerals. Whether that starting point tips over into a diagnosis depends, among other things, on something that can be measured, and sometimes adjusted. This paper is about the large group that carries the vulnerability without ever crossing the threshold into a diagnosis. It is a hypothesis and an invitation to test it. It should be read as exactly that, not as medical advice or a diagnostic manual, and it gives no instruction to any individual.

The diagnosis is not the deepest layer

A diagnosis is a cluster: a symptom-picture that resembles enough others to be given the same name. It is useful in a clinic, but it is not the most fundamental layer. Beneath the symptoms lies what the paper calls the substrate: the concrete mix of genes, enzymes and cofactors (vitamins and minerals) that decides how the brain's machinery actually computes. Two people can end up with exactly the same symptom-picture by two completely different biological routes. The cluster does not preserve the route that got you there.

The frame behind this builds on the same picture as the rest of the site, the one I explain with water. The brain is constantly running little races: several possible reactions run at the same time, and the one that crosses the line first wins. Every time a route wins, it carves its track a little deeper. How fast a race is settled depends on the pressure in the system. The substrate is the material the race runs on. The diagnosis is only the pattern that eventually comes out, if enough races fall the same skewed way.

The group no research sees

Here the paper follows the thought to its conclusion. If the substrate is fundamental, and the diagnosis is only what comes out, then there must exist a large group of people who carry the vulnerable substrate without crossing any threshold. Clinical research recruits on diagnoses, so that group is simply not something it is set up to see. It is large, and it is vulnerable by default. It is just uncounted.

The numbers from existing research show how large it is. Sub-threshold depression affects around 11 % of the population, roughly three times as many as have a current full-blown depression. Sub-threshold ADHD in childhood runs at about 18 %. The broader autism pattern is seen in 14 to 23 % of parents of autistic children. And it is not a harmless place to sit: of those with sub-threshold depression, around 18 % develop a full depression over time, against roughly 6 % of those with no symptoms. The vulnerability is real, it just has not been given a name yet.

One clear illustration is families. Genes are shared within a family, but the rest of the substrate (cofactor status, the capacity of the enzymes, history, environment) is not. So the same inherited variants can produce a full diagnosis in one child and a quite different, milder expression in a parent. ADHD is strongly heritable, but even identical twins do not always agree: same genetic makeup, different outcome. That is the cleanest proof that carrying the variants and getting the diagnosis are not the same thing.

Where the bottleneck sits

To make this more than a tidy thought, you have to point to where in the biology a bottleneck can sit. Take dopamine and noradrenaline, the signalling molecules that are central in ADHD among other conditions. They are built in a chain of steps, and each step needs a particular helper to run: iron and BH4 for the first and slowest step, B6 for the next, copper and vitamin C for the third. If the building work itself is held back at one of those helpers, the bottleneck sits at the source.

That explains something the paper uses as its central illustration. Medication such as methylphenidate works by letting the signalling molecule that has already been produced linger longer in the synapse. But if production itself is held back by a shortfall further down, you are pressing an undersupplied system to send signals it does not have enough material for. You are working downstream of the brake instead of releasing it. The frame predicts that some of the large variation in how people respond to such medication is tied to their cofactor status from the start.

The axis the paper develops most carefully is folate, B12 and the gene variant MTHFR: the so-called one-carbon cycle. It is chosen because it has the strongest existing evidence for an interplay between gene and cofactor. A review pooling many studies (Gilbody and colleagues, 2007) found that people with the slow MTHFR variant have a measurably raised risk of conditions including depression and schizophrenia. What is special about this particular cycle is that it is a bottleneck in two places at once: both for building signalling molecules and for the chemical tagging (methylation) that helps lay down tracks in the system. That is the frame's explanation for why the same cofactor support helps some people a great deal and others not at all. Those who are held back in both places respond more completely than those held back in only one.

Measure it, don't guess it

Here lies the most important discipline in the whole paper, and it is also what separates the hypothesis from what it can easily be mistaken for. The substrate must be measured: cofactor status by blood test, gene variants by genetic testing. It must never be inferred from symptoms. Thinking "I am tired, so I probably have an MTHFR variant" is exactly the biohacking error this hypothesis exists to displace, not to license. A version of the paper built on guessing from symptoms would not be the same paper. It would be a wellness piece with borrowed vocabulary.

The method is therefore a chain that starts at the measurement: measure the profile, work out which steps in the chain it points to, decide where there actually is a bottleneck, and only from there consider what might be worth testing. A gene variant on its own makes no difference. It is the combination of a variant and a low reading at the same place that points to a real link that can be supported. And the decision always belongs with a clinician, not with a website.

Why it has to be prevention

There is a reason the paper puts the weight on prevention rather than cure, and the reason is purely mechanical. As the other papers in the family explain: you cannot subtract anything from a human system, you can only add. A track that has been carved cannot be carved away again. Once the pressure has crossed the threshold and the race is running, it is too late to intervene in the race itself. So what works is what gets added before: a lower floor, competing experience, or preventing the race from starting at all.

Cofactor support below the threshold is prevention in its purest form: supporting the substrate before a skewed path has been run enough times to carve a deep track. And there is a cost to leaving the unseen group alone. A substrate below the threshold runs races every day that do not cross any clinical line, but each of them lays down a little track. Over years it can build up on a compensating route (overwork, over-control, self-medication) until that route starts to win on its own. That is the frame's account of why an unseen, untreated vulnerability sometimes shows up many years later as something else entirely.

What the paper actually does

The paper is a hypothesis and an invitation, not a treatment manual. It sets out nine testable predictions, and several of them can be examined on data that has already been collected, without gathering any new. Two of them are decisive: that it is the interplay between gene and measured cofactor status (not the genes alone) that decides whether the vulnerability tips over, and that a fresh, split-out analysis of trials that otherwise showed no effect should reveal a result in precisely the subgroup that is held back at the right link. If both fall, the core of the paper falls. That is how a frame is meant to be used: it says what can be tested, not what a particular person should do.

And to be explicit: this is neither a new diagnostic manual nor medical advice. It does not replace a professional assessment of the individual, and it recommends no particular dose of anything. If something here rings true about yourself or someone you care about, that is a conversation to have with a professional, not a conclusion to draw from a website.

What I don't know

There is no clinical co-author on the paper yet, and that is a real limitation: the frame is built by a theorist, not tested in a clinic. No new data has been collected for it either. It gathers existing findings (prevalences, gene studies, biochemistry) under one picture and points to where they could be tested together.

The biological claims are stated as predictions, not as something proven. That cofactor support matched to a measured profile works preventively is exactly the open question the paper asks to have tested, not something the frame delivers as a finished answer. The paper also develops only one axis in depth (folate, B12 and MTHFR); the other vitamins and minerals are listed as candidates for the same logic, not defended one by one. And the maths behind it is deliberately simplified. It shows the shape of the mechanism, but it is not calibrated to numbers you can compute further on. The next step is collaboration with people who can test the predictions properly.

Read the paper

The full article is freely available on Zenodo (concept DOI 10.5281/zenodo.20277290):

Read on Zenodo → · Technical version · Dansk version

Related on this site:

• Paper 1 (Friction Theory) — the framework behind races and tracks that this paper applies to biology.
• The Learning page — the same mechanics from the other end: how tracks are built up.
• The Memory page — why dumping information does not teach.

The family of clinical papers (same frame, different angles):

• Paper 8 — One mechanism behind many diagnoses: pressure, tracks and experience, and the principle of treating at the base rather than the top.
• Paper 8b — Compound race pathology: how several weak links in the same chain add up to disease over time.
• Paper 8c — Research programme: concrete study designs that can test the frame against reality.